CF PharmTech's (HKG:2652) profit attributable to owners of the parent fell to 2.5 million yuan for 2025 from 21.1 million yuan a year earlier, according to a Monday Hong Kong bourse filing.
Earnings per share came in at 0.0066 yuan, compared with 0.0569 yuan a year earlier.
Revenue declined to 432.5 million yuan from 607.8 million yuan in 2024.